EGFR and squamous cell carcinoma: The most relevant case is that of cetuximab, a chimeric IgG1 monoclonal antibody (mAb) against the epidermal growth factor receptor that is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck.